Benzinga··PrnewswirePrecigen Posts Strong Q1 Results as PAPZIMEOS Ramps to $21.6M Revenue
Precigen reports $21.6M in Q1 PAPZIMEOS revenue with 90%+ payer coverage. Net loss shrinks to $7.9M; company targets cash flow break-even by year-end.
PGENFDA approvalrevenue growth